Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Market Cap	197.41B -7.9%
Revenue (ttm)	16.72B +22.6%
Net Income	6.18B +27.1%
EPS	1.03 +26.4%
Shares Out	6.06B
PE Ratio	31.50
Forward PE	28.54
Dividend	0.43 (1.31%)
Ex-Dividend Date	Jul 3, 2026

Volume	8,689,777
Open	32.62
Previous Close	33.06
Day's Range	31.86 - 33.26
52-Week Range	28.06 - 44.22
Beta	0.53
Analysts	Strong Buy
Price Target	46.60 (+42.75%)
Earnings Date	Aug 18, 2026

About HKG:3692

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 9,347
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3692

Financial Performance

In 2025, HKG:3692's revenue was 15.03 billion, an increase of 22.57% compared to the previous year's 12.26 billion. Earnings were 5.56 billion, an increase of 27.07%.

Financial numbers in CNY

Analyst Summary

According to 22 analysts, the average rating for 3692 stock is "Strong Buy." The 12-month stock price target is $46.60, which is an increase of 42.75% from the latest price.

Price Target

$46.60

(42.75% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 21, 2026

Data Sources Report a data error